Higher-Valency Pneumococcal Conjugate Vaccines Likely To Yield Limited Impact In Decreasing Pneumococcal Colonization, Pediatric AOM, Study Finds

Infectious Disease Advisor (7/12, Nye) reported study findings published in the Pediatric Infectious Disease Journal show that “higher-valency pneumococcal conjugate vaccines are expected to have limited impact in reducing pneumococcal colonization and acute otitis media (AOM) in children.” Infectious Disease Advisor added, “Researchers conducted a prospective longitudinal cohort study between September 2021 and September 2023 to evaluate the anticipated effects of higher-valency pneumococcal conjugate vaccines (15- and 20-valent). Children (N=139) aged 6 to 36 months who were immunized with the 13-valent vaccine at 2, 4, and 6 months of age and received a booster dose at 12 to 15 months of age were eligible for inclusion.”